Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Cipriani

Showing results (1-10 of 228) with videos related to

Pageof 23
Sort By:
British Journal of Haematology|November 8, 2014
Stem cell therapies for systemic sclerosisPaola Cipriani, Piero Ruscitti, Roberto Giacomelli
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 2, 2022
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the AssociationClaudia Di Muzio, Paola Cipriani, Piero Ruscitti
Expert Opinion on Pharmacotherapy|September 20, 2022
Perspectives on the use of non-biological pharmacotherapy for adult-onset Still's diseaseIlenia Di Cola, Paola Cipriani, Piero Ruscitti
BMC Rheumatology|September 25, 2020
Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know?Salvatore Di Bartolomeo, Francesco Carubbi, Paola Cipriani
Rheumatology (Oxford, England)|October 6, 2018
Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?Roberto Caporali, Veronica Codullo, Paola Cipriani, et al.
Clinical and Experimental Rheumatology|March 5, 2021
Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trialPiero Ruscitti, Onorina Berardicurti, Paola Cipriani, et al.
Seminars in Immunology|July 5, 2022
The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patientsPiero Ruscitti, Onorina Berardicurti, Roberto Giacomelli, et al.
Autoimmunity Reviews|September 17, 2020
Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectivesPaola Di Benedetto, Piero Ruscitti, Paola Cipriani, et al.
Journal of Neuroscience Research|November 25, 2021
Sex differences in early language delay and in developmental language disorderAnna Maria Chilosi, Paola Brovedani, Paola Cipriani, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et alPaola Cipriani, Paola Di Benedetto, Vasiliki Liakouli, et al.
Pageof 23

Showing results (1-10 of 228) with videos related to

Sort By:
Pageof 23
British Journal of Haematology|November 8, 2014
Stem cell therapies for systemic sclerosisPaola Cipriani, Piero Ruscitti, Roberto Giacomelli
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 2, 2022
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the AssociationClaudia Di Muzio, Paola Cipriani, Piero Ruscitti
Expert Opinion on Pharmacotherapy|September 20, 2022
Perspectives on the use of non-biological pharmacotherapy for adult-onset Still's diseaseIlenia Di Cola, Paola Cipriani, Piero Ruscitti
BMC Rheumatology|September 25, 2020
Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know?Salvatore Di Bartolomeo, Francesco Carubbi, Paola Cipriani
Rheumatology (Oxford, England)|October 6, 2018
Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?Roberto Caporali, Veronica Codullo, Paola Cipriani, et al.
Clinical and Experimental Rheumatology|March 5, 2021
Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trialPiero Ruscitti, Onorina Berardicurti, Paola Cipriani, et al.
Seminars in Immunology|July 5, 2022
The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patientsPiero Ruscitti, Onorina Berardicurti, Roberto Giacomelli, et al.
Autoimmunity Reviews|September 17, 2020
Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectivesPaola Di Benedetto, Piero Ruscitti, Paola Cipriani, et al.
Journal of Neuroscience Research|November 25, 2021
Sex differences in early language delay and in developmental language disorderAnna Maria Chilosi, Paola Brovedani, Paola Cipriani, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et alPaola Cipriani, Paola Di Benedetto, Vasiliki Liakouli, et al.
Pageof 23